News Releases - CSL
WEB4 days ago · Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine. Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.
Global Newsroom | CSL
WEBCSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. Jun 11, 2024 - CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States.
News Releases - CSL
WEBApr 17, 2024 · Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
News Releases | CSL
WEBPart of a A$2 billion infrastructure investment program in Australia undertaken by CSL over the past four years, the facility will house more than 850 professionals dedicated to protecting public health and bringing life-saving innovative therapies to those in need.
News Releases | CSL
WEBStudy results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year. Garadacimab underscores CSL's promise to develop innovative medicines for people living with rare diseases like HAE, a community CSL has been serving for 40 years.
Celebrating CSL's New Research and Development Center in …
WEBFor three years, anticipation has been building for the completion of CSL’s new R&D site in Marburg, Germany. On Tuesday, the doors opened for a launch event that showcased the state-of-the-art space, which will be powered by 500 R&D employees.
News Releases | CSL
WEBNov 2, 2022 · CSL revealed progress and plans in advancing assets that have the potential to disrupt current standards of care in its areas of focus (immunology, haematology, respiratory, cardiovascular and metabolic, transplant, nephrology, vaccines) using its strategic scientific platforms (plasma protein technology, …
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial ...
WEBFeb 11, 2024 · Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
News Releases - CSL
WEBMay 30, 2024 · CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season. CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a... May 21, 2023.
News Releases | CSL
WEBCSL Seqirus’ $800m+ innovative vaccine and antivenom manufacturing facility in Australia reaches major construction milestone. Melbourne, Monday 22 May. CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’.